Shanghai Xuerong Bio-Technology Co Ltd (300511) - Total Assets
Based on the latest financial reports, Shanghai Xuerong Bio-Technology Co Ltd (300511) holds total assets worth CN¥3.61 Billion CNY (≈ $527.99 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Shanghai Xuerong Bio-Technology Co Ltd (300511) shareholders funds for net asset value and shareholders' equity analysis.
Shanghai Xuerong Bio-Technology Co Ltd - Total Assets Trend (2012–2024)
This chart illustrates how Shanghai Xuerong Bio-Technology Co Ltd's total assets have evolved over time, based on quarterly financial data. Check Shanghai Xuerong Bio-Technology Co Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Shanghai Xuerong Bio-Technology Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Shanghai Xuerong Bio-Technology Co Ltd's total assets of CN¥3.61 Billion consist of 14.2% current assets and 85.8% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 4.4% |
| Accounts Receivable | CN¥31.39 Million | 0.8% |
| Inventory | CN¥325.34 Million | 8.4% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥299.63 Million | 7.8% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Shanghai Xuerong Bio-Technology Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 300511 stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shanghai Xuerong Bio-Technology Co Ltd's current assets represent 14.2% of total assets in 2024, an increase from 0.0% in 2012.
- Cash Position: Cash and equivalents constituted 4.4% of total assets in 2024, up from 3.6% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, a decrease from 12.0% in 2012.
- Asset Diversification: The largest asset category is inventory at 8.4% of total assets.
Shanghai Xuerong Bio-Technology Co Ltd Competitors by Total Assets
Key competitors of Shanghai Xuerong Bio-Technology Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ningxia Xiaoming Agriculture & Animal Husbandry Co.Ltd
SHE:300967
|
China | CN¥1.66 Billion |
|
MOWI ASA SP.ADR
F:PNDA
|
Germany | €10.23 Billion |
|
Fujian Wanchen Biotechnology Co. Ltd
SHE:300972
|
China | CN¥10.76 Billion |
|
Pt Pradiksi Gunatama Tbk
JK:PGUN
|
Indonesia | Rp2.51 Trillion |
|
Yuan Longping High-tech Agriculture Co Ltd
SHE:000998
|
China | CN¥25.17 Billion |
|
Zhongnongfa Seed Industry Group Co Ltd
SHG:600313
|
China | CN¥5.73 Billion |
|
ShenZhen Kondarl Group Co Ltd
SHE:000048
|
China | CN¥10.14 Billion |
|
Molinos Agro SA
BA:MOLA
|
Argentina | AR$1.01 Trillion |
Shanghai Xuerong Bio-Technology Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.31 | 0.53 | 1.10 |
| Quick Ratio | 0.08 | 0.27 | 0.76 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-1.05 Billion | CN¥-780.55 Million | CN¥112.17 Million |
Shanghai Xuerong Bio-Technology Co Ltd - Advanced Valuation Insights
This section examines the relationship between Shanghai Xuerong Bio-Technology Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.08 |
| Latest Market Cap to Assets Ratio | 0.15 |
| Asset Growth Rate (YoY) | -16.2% |
| Total Assets | CN¥3.85 Billion |
| Market Capitalization | $570.16 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shanghai Xuerong Bio-Technology Co Ltd's assets below their book value (0.15x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Shanghai Xuerong Bio-Technology Co Ltd's assets decreased by 16.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Shanghai Xuerong Bio-Technology Co Ltd (2012–2024)
The table below shows the annual total assets of Shanghai Xuerong Bio-Technology Co Ltd from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.85 Billion ≈ $564.04 Million |
-16.24% |
| 2023-12-31 | CN¥4.60 Billion ≈ $673.44 Million |
+13.02% |
| 2022-12-31 | CN¥4.07 Billion ≈ $595.87 Million |
-6.18% |
| 2021-12-31 | CN¥4.34 Billion ≈ $635.10 Million |
-4.92% |
| 2020-12-31 | CN¥4.56 Billion ≈ $667.95 Million |
+18.81% |
| 2019-12-31 | CN¥3.84 Billion ≈ $562.18 Million |
-1.30% |
| 2018-12-31 | CN¥3.89 Billion ≈ $569.60 Million |
+1.46% |
| 2017-12-31 | CN¥3.84 Billion ≈ $561.38 Million |
+55.91% |
| 2016-12-31 | CN¥2.46 Billion ≈ $360.06 Million |
+38.64% |
| 2015-12-31 | CN¥1.77 Billion ≈ $259.70 Million |
+14.60% |
| 2014-12-31 | CN¥1.55 Billion ≈ $226.62 Million |
+5.82% |
| 2013-12-31 | CN¥1.46 Billion ≈ $214.15 Million |
+3.79% |
| 2012-12-31 | CN¥1.41 Billion ≈ $206.32 Million |
-- |
About Shanghai Xuerong Bio-Technology Co Ltd
Shanghai Xuerong Biotechnology Co.,Ltd., together with its subsidiaries, engages in the research and development, cultivation and sale of fresh edible mushrooms in the People's Republic of China. It offers enoki mushrooms; shiitake mushrooms, including oyster mushrooms, white jade mushrooms and seafood mushrooms; king oyster mushrooms; and velvet mushrooms, as well as Pleurotus eryngii and Flammu… Read more